Departement of Internal Medicine-Hematooncology, University Hospital Brno, Masaryk University, Brno, Czech Republic.
Ann Hematol. 2010 Apr;89(4):385-9. doi: 10.1007/s00277-009-0834-3. Epub 2009 Sep 26.
Angiogenesis plays a significant role in the pathogenesis of multiple myeloma (MM). We have measured concentrations of angiogenesis activators, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor, and hepatocyte growth factor (HGF), and inhibitors, including endostatin, thrombospondin-1 (TSP-1), and angiostatin in the peripheral and bone marrow blood of MM patients at diagnosis and after high-dose chemotherapy. We have analyzed 96 patients with secretory MM. Serial measurements of angiogenesis factors/inhibitors were analyzed in the plasma by subgroups based on the best treatment response. Concentrations of angiogenic factors were determined in the peripheral blood and bone marrow plasma. There were significant decreases of VEGF and HGF levels and a significant increase in TSP-1 concentrations in the bone marrow plasma of patients who achieved complete or very good partial response in contrast to those who had partial or no response. VEGF and HGF levels decrease but those of TSP-1 increase after successful treatment for MM, indicating a reduction in the rate of angiogenesis.
血管生成在多发性骨髓瘤（MM）的发病机制中起着重要作用。我们已经测量了血管生成激活剂（包括血管内皮生长因子（VEGF）、碱性成纤维细胞生长因子和肝细胞生长因子（HGF））和抑制剂（包括内皮抑素、血小板反应蛋白-1（TSP-1）和血管抑素）在多发性骨髓瘤患者诊断时和高剂量化疗后的外周血和骨髓血中的浓度。我们分析了 96 例分泌性 MM 患者。根据最佳治疗反应，通过亚组分析了血管生成因子/抑制剂的连续测量。在血浆中确定了血管生成因子的浓度。与部分缓解或无缓解的患者相比，完全缓解或非常好部分缓解的患者骨髓血浆中 VEGF 和 HGF 水平显著降低，而 TSP-1 浓度显著升高。在成功治疗多发性骨髓瘤后，VEGF 和 HGF 水平下降，但 TSP-1 水平升高，表明血管生成率降低。
